Paraaortic lymph node recurrence in lung SCC by Kajiura, Koichiro et al.
INTRODUCTION
Abdominal paraaortic lymph node metastasis is defined as a
distant metastasis in the General Rule for Clinical and Pathological
Record of Lung Cancer, 8th Edition (1). In this disease, the direc-
tion of lymph flow in the thoracic cavity favored the cranial side,
although lymph flow directionality is complicated. We report a rare
case of solitary paraaortic lymph node recurrence after radical sur-
gery for lung squamous cell carcinoma (SCC).
CASE REPORT
A 63-year-old man, who displayed an abnormal shadow on chest
radiography, was referred to our hospital. Past disease history in-
cluded hypertension, hyperlipidemia, type 2 diabetes mellitus, and
emphysema. A chest computed tomography (CT) exam showed a
22 × 18 mm nodule in the right S10 segment and bilateral interstitial
pneumonia (Fig. 1). Histological findings, via bronchoscopy, re-
vealed lung SCC. Positron emission tomography - CT (PET/CT)
showed a concentration of fluorodeoxyglucose (FDG) only in the
primary lesion, and the maximum standard uptake value (SUVmax)
was 8.28 in the lesion. The interstitial pneumonia was complicated
by high levels of disease markers, including KL-6 (610 U/ml,
normal range500 U/ml) and SP-D (264 ng/ml, normal range
110 U/ml). We diagnosed the patient with lung SCC cT1cN0M0,
stage IA3, using the General Rule for Clinical and Pathological
Record of Lung Cancer, 8th Edition (1) and performed a video-
assisted right lower lobectomy (ND2a-1). Pathological findings
showed poorly differentiated SCC, pl0, pm0, n0, pT1c (3 cm),
pT1cN0M0 pstage IA3 ; EGFR mutation and ALK translocation
were negative. Adjuvant therapy was not performed for interstitial
pneumonia, and a follow-up PET/CT, which was performed 15
months after the operation, showed a single FDG-concentrated
area in the paraaortic lymph node. The SUVmax was 5.6 in the
lesion (Fig. 2), and enhanced CT, gastrointestinal fiberscopy, and
colon fiberscopy showed no malignant primary lesions in the ab-
dominal cavity. We suspected that the patient had an atypical, soli-
tary paraaortic lymph node recurrence of the lung cancer. We per-
formed a paraaortic lymph node biopsy, via open laparotomy, to
achieve a precise diagnosis and determine the cancer gene status.
The target lymph nodes were identified in the round celiac trunk
and superior mesenteric artery, and two adjacent lymph nodes
were resected (Fig. 3). Pathological findings showed that both
paraaortic lymph nodes contained poorly differentiated SCCs,
which were thought to have metastasized from the lung cancer
(Fig. 4). The lymph nodes were EGFR mutation negative, ALK
translocation negative, and ROS1 mutation negative, and the tumor
proportion score (TPS) of PD-L1 was 55%. We administered pem-
brolizumab to the patient as first - line therapy, because the TPS of
PD-L1 was greater than 50% (2) ; however, the patient presented
with interstitial pneumonia, with an unusual pattern, as a complica-
tion. Following treatment with pembrolizumab for half of a year, the
patient did not show any recurrence, but experienced grade 1 hypo-
thyroidism as an adverse effect from pembrolizumab, according to
the Common Terminology Criteria for Adverse Events (CTCAE) v
4.0.
DISCUSSION
Lymph node lung cancer recurrences tend to occur in reginal
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lymph nodes, such as the N1, N2, or N3 regions. Abdominal
paraaortic lymph node recurrences are defined as distant metastasis
by the General Rule for Clinical and Pathological Record of Lung
Cancer, 8th Edition (1). Solitary abdominal paraaortic lymph node
recurrences are rare after pathological N0 surgery, although some-
times present as complications of multiple systemic metastases.
Anatomically, the right S10 segment of the lung was near the celiac
trunk lymph node, as a solitary recurrence. The lymph and thoracic
ducts connect the mediastinum and the abdominal cavity, and
penetrate the diaphragm via the esophagus hiatus, aortic hiatus,
and foramen of vena cava. However, this pattern of lymph flow is
rare, and generally, lymph flow is directed into the cranial side of
the thoracic cavity. In addition, the surgical findings of this case
showed no obvious lymph ducts near the tumor, toward the medi-
astinum. Therefore, it may be possible that cancer cells at the S10
region of the lung metastasized via this diaphragm route. Nowa-
days, sentinel lymph node navigation systems have been reported
(3), and if sentinel navigation systems of lung cancer can be estab-
lished, they would be useful for this case, where we suspected a
specific pattern of lymph flow into the thoracic cavity.
We initially suspected that the lymph node metastasis originated
from the malignancy in the abdominal organs or lymphadenitis ;
however, additional examinations did not reveal malignancies in
the abdominal organs. We performed lymph node dissection to
achieve a precise diagnosis and determine the gene mutation
status. We identified a substantial increase in the TPS of PD-L1,
and therefore, administered an immune checkpoint inhibitor as a
personalized therapy.
Figure 1. CT scan showing a 2-cm tumor in the right S10, with
bilateral interstitial pneumonia.
Figure 2. PET/CT scan showing a FDG-concentrated region in the
paraaortic lymph node. The SUVmax was 5.6.
Figure 3. Resected specimens. The black line is 20 mm.
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Figure 4. HE staining (×400). 4a) Squamous cell carcinoma of the
paraaortic lymph node. 4b) Squamous cell carcinoma of the lungs, at first
surgery.
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Currently, biopsies are important for confirming diagnoses and
identifying genetic mutations and immune checkpoint gene ex-
pression statuses. Generally, EGFR, ALK, and ROS1 should be in-
vestigated as genetic mutations of lung cancer, because of the avail-
able therapeutics in the Japanese market in 2017. In future, we may
need to examine a greater number of genetic mutations using next
generation sequencing (4-6). Additionally, it is essential to identify
the TPS of PD-L1 for immune checkpoint inhibitors, especially in
squamous cell carcinomas (7, 8), and re-biopsies are commonly
performed upon EGFR-tyrosine kinase inhibitor (TKI) treatment
failure. Re-biopsies can successfully identify the resistance gene,
for example EGFR T790M, and the accuracy of re-biopsies have
been reported to be 79.5-80.7% (9, 10). If the T790M mutation is
identified in cancer tissues, we can administer osimertinib to the
patient (11, 12). Biopsies of unclear malignant lesions are impor-
tant for such cases, and especially for unexpected metastatic le-
sions. Furthermore, biopsies of aggressive diseases allow precise
diagnoses, identification of target gene mutation statuses, and de-
termination of the TPS of PD-L1.
Biopsies of abdominal paraaortic lymph nodes are usually per-
formed via laparotomy, as in this case. There are no reports of
percutaneous needle biopsies and/or endoscopic needle biopsies
for abdominal paraaortic lymph nodes.
In this case, we reported the rare recurrence of solitary ab-
dominal paraaortic lymph node from lung SCC. It is of increasing
importance to perform biopsies for suspicious recurrent lesions,
because biopsies not only allow improved diagnoses but also allow
the identification of target gene expression statuses and improve
diagnoses over clinical imaging tools.
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